ResMed (NYSE:RMD) will post its quarterly earnings results after the market closes on Monday, January 22nd. Analysts expect ResMed to post earnings of $0.78 per share for the quarter.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.66. The firm had revenue of $523.66 million for the quarter, compared to analyst estimates of $506.08 million. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The business’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 EPS. On average, analysts expect ResMed to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

ResMed (NYSE RMD) opened at $88.68 on Friday. The firm has a market capitalization of $12,580.00, a P/E ratio of 35.90, a price-to-earnings-growth ratio of 2.25 and a beta of 0.78. ResMed has a 1 year low of $62.64 and a 1 year high of $89.72. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.86 and a current ratio of 4.72.

In related news, Director Peter C. Farrell sold 118,392 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $82.70, for a total transaction of $9,791,018.40. Following the transaction, the director now directly owns 306,615 shares of the company’s stock, valued at approximately $25,357,060.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $85.36, for a total value of $106,700.00. Following the transaction, the chief financial officer now directly owns 79,572 shares in the company, valued at $6,792,265.92. The disclosure for this sale can be found here. Insiders have sold a total of 158,929 shares of company stock worth $13,181,009 over the last three months. 1.77% of the stock is owned by insiders.

Several research analysts have weighed in on the company. Zacks Investment Research lowered ResMed from a “buy” rating to a “hold” rating in a research report on Friday. BMO Capital Markets boosted their price target on ResMed to $82.00 and gave the stock a “market perform” rating in a research report on Tuesday, December 12th. JPMorgan Chase & Co. boosted their price target on ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a research report on Monday, October 30th. Barclays boosted their price target on ResMed from $68.00 to $70.00 and gave the stock an “underweight” rating in a research report on Friday, October 27th. Finally, Northland Securities reissued a “sell” rating and set a $55.00 target price on shares of ResMed in a report on Friday, October 27th. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $70.57.

COPYRIGHT VIOLATION WARNING: “ResMed (RMD) Scheduled to Post Quarterly Earnings on Monday” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/20/resmed-rmd-scheduled-to-post-quarterly-earnings-on-monday.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Earnings History for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.